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Background: spa typing is a common genotyping tool for methicillin-resistant Staphylococcus aureus (MRSA) in
Europe. Given the high prevalence of dominant clones, spa-typing is proving to be limited in its ability to
distinguish outbreak isolates from background isolates. New molecular tools need to be employed to improve
subtyping of dominant local MRSA strains (e.g., spa type t003).
Methods: Phylogenetically critical, or canonical, SNPs (can-SNPs) were identified as subtyping targets through
sequence analysis of 40 MRSA whole genomes from Luxembourg. Real-time PCR assays were designed around
target SNPs and validated using a repository of 240 previously sub-typed and epidemiologically characterized
Luxembourg MRSA isolates, including 153 community and hospital isolates, 69 isolates from long term care (LTC)
facilities, and 21 prospectively analyzed MRSA isolates. Selected isolates were also analyzed by whole genome SNP
typing (WGST) for comparison to the SNP assays and other subtyping techniques.
Results: Fourteen real-time PCR assays were developed and validated, including two assays to determine presence
of spa t003 or t008. The other twelve assays successfully provided a high degree of resolution within the t003
subtype. WGST analysis of the LTC facility isolates provided greater resolution than other subtyping tools,
identifying clusters indicative of ongoing transmission within LTC facilities.
Conclusions: canSNP-based PCR assays are useful for local level MRSA phylotyping, especially in the presence of
one or more dominant clones. The assays designed here can be easily adapted for investigating t003 MRSA strains
in other regions in Western Europe. WGST provides substantially better resolution than other typing methods.
Keywords: spa t003, MRSA, SNP assays, WGST, Luxembourg, Phylotyping, Molecular epidemiologyBackground
The evolution of methicillin resistant Staphylococcus aureus
(MRSA) is well documented to be heavily influenced by the
success of apparently highly fit clones [1]. Local MRSA
populations are frequently dominated by such successful
clones, which will vary depending on geographic location
[2]. These dominant clones typically shape much of the en-
demic and epidemic spread of this pathogen. This paradigm
provides obstacles to performing accurate and informative
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distribution, and reproduction in any mediumnamely an inability to separate outbreak strains from back-
ground strains as well as a inability to examine differences
among outbreak strains.
spa typing has become a popular genotyping tool in
Europe due to its portability and reproducibility [3,4]. spa
typing is based on the polymorphic direct repeats found
in the staphylococcal protein a (spa) gene. Differentiation
is based on repeat changes due to point mutations, inser-
tions, deletions and duplications [3]. Genotyping with spa
has shown to have good correlation with multi-locus se-
quence typing (MLST), both of which have generally ac-
ceptable phylogenetic associations, based on population
data derived from whole genome sequencing [4]. MLST,
spa, and other typing methods have therefore provided antral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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of S. aureus and establishing the major clades, or clonal
clusters and dominant sub-clades, or clones, in the global
population [5-7]. Unfortunately, like MLST, spa typing
is limited in its resolving power; for instance in a recent
survey of spa types throughout Europe, five spa types
accounted for nearly half of all MRSA strains identified
[8]. Therefore, these methods are unable to provide suffi-
cient utility for resolving isolates in local epidemic situa-
tions [6]. In addition, the negative impact of homoplasies,
(e.g., character state conflict resulting from convergent
evolution) has been well established in spa typing [2,9].
While numerous spa types have been seen in
Luxembourg, spa t003 is clearly the current dominant
genotype [10]. spa t003 is a highly successful clonal
population that was introduced to Europe in the mid
1990s [7] where it has successfully replaced spa t008
as the dominant clone in neighboring countries such
as Germany [11]. As such, spa typing MRSA strains
provides limited utility for molecular epidemiology in
Luxembourg, constraining health officials’ ability to ac-
curately detect and respond to outbreaks in hospitals
and the community. Here we describe efforts to develop
improved genotyping for MRSA isolates, particularly within
the spa t003 clone in Luxembourg, based initially on whole
genome sequencing to precisely define the population
structure within this narrow clonal complex. Next we iden-
tify phylogenetically critical canonical SNPs (canSNPs) for
branch-specific PCR-based assays [12] for sensitive and
high through put analysis. Note: spa t003 is predominantly
composed of MLST sequence types ST225 and ST710 [10];
for clarity we refer primarily to spa type rather than other
genotyping nomenclature, unless otherwise stated.Methods
Selection of strains
Four sets of MRSA strains isolated in Luxembourg were
selected from the Laboratoire National de Santé (LNS)
strain repository, including an Assay Development Panel,
Assay Validation Panel, Long Term Care Facility collec-
tion, and a Prospective Hospital isolate collection (see
Table 1). The Assay Development Panel included 40
retrospectively collected isolates, including 10 pairs of
hospital-, time-, and genotype-linked (by spa and MLST)
t003 strains; 5 liked t008 pairs; and 10 non-t003 or t008Table 1 MRSA strain sets used for development and validatio
Strain set Isolate no. sp
Assay Development 40 t0
Assay Validation 153 t0
Long Term Care Facility 69 t0
Prospective Hospital 21 t0isolates (Additional file 1: Table S1). The Assay Validation
Panel consisted of 153 predominantly spa t003 strains
from the LNS repository (including community and health
care associated strains, Additional file 2: Table S2). The
isolates for both of these panels were collected as part of
standard of care from Luxembourg hospitals and submit-
ted to the LNS as the national microbiology reference la-
boratory. The Long Term Care (LTC) Facility collection
included 69 previously described strains from 17 long
term care facilities in Luxembourg, with nearly half the
strains typed as t003 [10] (Additional file 3: Table S3).
These isolates were part of a nationally representative
cross-sectional MRSA prevalence study in LTCF facilities
was conducted from February to June 2010 in the Grand
Duchy of Luxembourg [10]. The Prospective Hospital col-
lection included 21 isolates submitted to LNS in March
and April of 2012 from three Luxembourg Hospitals
(Additional file 4: Table S4). The isolates from the pro-
spective hospital collection were collected as part of stand-
ard of care from Luxembourg hospitals and submitted to
the LNS as the national microbiology reference laboratory.
No patient identifiers were linked to any isolates, all iso-
lates were stored as bacterial isolates and no human sub-
jects were involved in the research.
DNA extraction
S. aureus strains were grown on nutrient agar overnight.
Genomic DNA was extracted using a Qiagen DNeasy
Blood and Tissue Kit as per manufacturer’s instructions
(Qiagen, Valencia, CA), with the addition of lysostaphin
(Sigma-Aldrich, St Louis, MO) at 200 ug/mL to the en-
zymatic lysis buffer and an incubation from 1 to 5 hours.
Sequencing library preparation/sequencing
Following extraction, adequate DNA presence was verified
by visualization via agarose gel electrophoresis. Extracted
DNA quantities were normalized to 10 to 15 ng/uL in
200 uL, for final yields of 2 to 3 ug prior to library prepa-
ration. DNA samples were prepared for multiplexed,
paired-end sequencing on the GAIIx Genome Analyzer
(Illumina, Inc, San Diego, CA) following the manufac-
turers protocol. For each isolate, 1-5 μg dsDNA in 200 μl
was sheared and then purified using the QIAquick PCR
Purification kit (Qiagen). Enzymatic processing of the
DNA followed the guidelines as described in the Illuminan of PCR assays
a Types present (no. per type)
03 (20); t008 (9); t136 (1); t011 (4); t002 (2); t306 (2); t032 (1); t051 (1)
03 (135); t008 (18);
03 (33); t032 (3); t045 (3); t899 (3); t105 (2); t002 (2); t010 (2); t3803 (2); t3106 (2)
03 (21)
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New England Biolabs (New England Biolabs, Ipswich,
MA) and the oligonucleotides and adaptors were obtained
from Illumina. After ligation of the adaptors, the DNA
was run on a 2% agarose gel for 2 hours, after which a gel
slice containing 500-600 bp fragments of each DNA sam-
ple was isolated and purified using the QIAquick Gel Ex-
traction kit (Qiagen). Individual libraries were quantified
with qPCR on the ABI 7900HT (Life Technologies Corp.,
Carlsbad, CA) using the Kapa Library Quantification Kit
(Kapa Biosystems, Woburn, MA). Based on the individ-
ual library concentrations, equimolar pools of 12 to 24 S.
aureus libraries were prepared at a concentration of at least
1 nM. To ensure accurate loading onto the flowcell, the
same quantification method was used to quantify the final
pools. The pooled libraries were sequenced on the Illumina
GAIIx using “Genomic DNA sequencing primer V2” for
36 cycles. A 100 bp read paired-end run was used for all
isolates. An average depth of coverage of 80× was obtained
for all samples when raw reads were aligned against a refer-
ence. The sequence data has been deposited in a public
data base [GenBank: SAMN02203196-SAMN0223319].Sequence alignment and SNP detection
Illumina WGS data sets were aligned against the Mu50 and
04-02981 reference genomes [13,14] using the short-read
alignment component of the Burrows-Wheeler Aligner
(BWA) alignment tool [15]. Reads containing insertions or
deletions, and those mapping to multiple locations in the
reference were removed from the final alignments. SNP de-
tection was conducted using SolSNP [16], a publically avail-
able in-house developed tool. SNPs were excluded if they
did not meet a minimum coverage of 10× and if the variant
was present in less than 90% of the base calls for that pos-
ition. Additionally, duplicated regions were identified by a
self-comparison of reference genomes using MUMmer ver-
sion 3.22 and SNPs within these repetitive regions were
removed. Phylogenetically informative SNPs, from coding
and non-coding regions, were extracted from the align-
ments also using SolSNP. Finally, loci that were not present
in all strains were removed and a matrix containing the
remaining orthologous SNPs was generated.Phylogeny construction
Phylogenetic trees were developed using the maximum par-
simony analysis in MEGA5 [17] with nonparametric boot-
strapping using 1000 bootstrap replicates. The first overall
tree was constructed, including fifteen closely related publi-
cally available whole genome sequences (Additional file 5:
Table S5), and all trees were rooted with the most basal taxa
or group of taxa in each analysis set. The tree matrix data
have been deposited in a public database [Dryad Repository:
http://dx.doi.org/10.5061/dryad.73p5d].SNP Assay design and validation
Candidate canSNPs (i.e., canonical SNPs) demarcating
each of the major phylogenetic branches were identified
using the in-house script. Real-Time PCR primers and
TaqMan minor groove binding allele specific probes were
designed in Primer Express software v3.0 (Life Technologies
Corp.) for each of the candidate SNPs (Additional file 6:
Table S6). SNP assays were screened across the initial panel
of 40 strains that were whole genome sequenced. Real-
Time PCR was conducted on ABI 7900HT (Life Technolo-
gies Corp.) using TaqMan Genotyping Master Mix (1×)
(Life Technologies Corp.), 900 nM forward and reverse
primers, and 200 nM of each probe. After screening across
the initial panel, successful assays were selected for further
validation and screened across the larger panel of 153 pre-
dominantly spa t003 strains, the panel of 69 strains from




The whole genome sequence analysis of the Assay De-
velopment strain panel provided for a robust phylogen-
etic tree with well-supported clades and sub-clades, as well
as complete discriminations among all strains (Figures 1,
and 2). These analyses generally showed phylogenetic con-
cordance with the MLST and spa typing results for these
strains (Figure 1). The phylogenetically critical SNPs defin-
ing separate clades (i.e., the synapomorphic SNPs found
along the branches leading to each clade) provided a
candidate canSNP pool for clade-specific assay develop-
ment. Multiple SNPs were selected from each of six major
branches for initial assay development (Figure 2). Valid-
ation of the initial six assays with the Validation Panel
showed 29 strains (19%) unresolved by the first round of
spa t003 assays. The 29 unresolved strains were also se-
quenced and the genomes were added to the spa t003
phylogeny to establish improved resolution (Figure 3) -
resulting in a total of 12 branches within t003 for which as-
says 2 were produced.
These twelve spa t003 subtyping assays, plus assays to
distinguish t003 from t008 (see Additional file 7: Figure
S1), were screened across the 153 strain Assay Validation
panel with greatly improved resolution (Table 2). The
canSNP assay results indicate only three (Lux11-12; Lux13-
14; Lux19-20) of ten hospital- and genotype-linked t003
isolate pairs from the original Assay Development panel
(Additional file 1: Table S1) were actually phylogenetically
linked (one of the isolates from the tenth pair would not
amplify and therefore was not likely a match to its counter-
part isolate). The t003 subtyping assays provided specific
identification results for 29 of 30 LTC Facility isolates ori-
ginally subtyped as t003 (Figure 4), and for all 21 Prospec-
tive Hospital isolates (Additional file 4: Table S4).
Figure 1 (See legend on next page.)
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Figure 1 Whole genome SNP Phylogeny of Assay Development Panel isolates along with fifteen publically available genomes. The
corresponding MLST (black) and spa types (red) are noted next to the strains. The phylogenetic relationships are based on a total of 98,768 SNPs
out of which 59,284 were parsimony informative with a CI = 0.65. Numbers next to branches are bootstrap values of 100 replicates. Bar length
indicates number of SNPs.
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typing (WGST) of the LTC Facility collection showed
concordant results, with the WGST (Figure 4) providing
higher resolution than the more rapid and less expensive
canSNP assays, and both showing greater resolution than
spa typing and MLST (Additional file 3: Table S3). WGST
provided distinct subtypes for each individual strain while
establishing phylogenetic relationships between strains. Ad-
ditionally, WGST identified multiple genomically related
clades within in the LTC Facility collection, identifying pos-
sible outbreak clusters within different facilities (Figure 4).
Discussion
We established that canSNP typing, with real-time PCR
assays based on phylogeny-defining SNPs, is more in-
formative for subtyping dominant MRSA strains in
Luxembourg than other available typing systems. The 12
PCR assays are based on distinct phylogenetic branches
identified from the analysis of 69 MRSA whole genomes.
These assays distinguished strains that are typically typed
as spa t003 or t008, as well as provided resolution within
t003 (Figure 1). The discriminatory power of these assaysFigure 2 Phylogenetic (A) and topology (B) trees of Assay Developmen
development panel. The phylogenetic relationships are based on a total of 19
Numbers next to branches are bootstrap values of 100 replicates. Branch locawas demonstrated by the assignment of specific genotypes
for 147 of 149 isolates that had been previously typed only
as spa type t003. As such, the use of these assays provides
both genotype (assignment of genetic similarity) and phy-
lotype (determination of phylogenetic relationships). A re-
cent study [11] identified similar results with the ability to
resolve a single distinct sub-clade (named t003-X) within
t003 in Germany, using three SNP assays. This particular
sub-clade was not identified in the sequenced Luxembourg
strains from a bioinformatic analysis of the three SNPs
that distinguish that sub-clade (data not shown). As the
SNPs identified in this study are presumed to be canonical
(branch, clade, or lineage specific) [12], and are useful at
resolving numerous clades within t003, it is likely that they
will be also useful for genotyping t003 strains in Germany
and other European countries with a dominant t003 strain
population.
Previous studies have found it necessary to build in nu-
merous assumptions to determine the presence of out-
breaks based on spa typing. For example, Harmsen [18]
used spa typing to describe MRSA at a German university
hospital for two study periods and determined that at strains (spa t003 only). Tree includes strains from initial assay
37 SNPs out of which 527 were parsimony informative with a CI = 0.84.
tions of first six assay SNP targets are indicated with a red triangle.
Figure 3 (See legend on next page.)
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Figure 3 Final spa t003 phylogeny with SNP assay targets. The phylogenetic relationships are based on a total of 1154 SNPs out of which
193 were parsimony informative with a CI = 0.98. Branch locations of the 12 validated spa t003 subtyping assays are indicated with a red triangle.
Tree includes 29 additional genomes from Assay Validation Panel to increase resolution within t003.
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type were seen within 9 days of each other. We confirm
the ability to separate hospital-linked strain pairs, using
the SNP assays, that were previously indistinguishable by
spa typing, MLVA, and MLST. Lacking such data, public
health and laboratory officials would have possibly as-
sumed direct genetic linkages in the other 12 pairs, and
falsely suspecting transmission or shared exposure source.
This provides evidence that these SNP-based real-time as-
says will improve the molecular epidemiologic response to
suspect outbreaks of t003 MRSA strains.
With the SNP-based assays, there is still apparent sub-
clonal dominance with certain genotypes, particularly the
003-D and 003-G subtypes, which represented 31-52%
and 29-37% of t003 stains, respectively, depending on iso-
late panel (Table 2, Additional file 4: Table S4, Figure 4).
Continued monitoring will be needed to determine if this
dominance is stable. If it is, then additional SNP assays
within these subpopulations can be developed (the canon-
ical SNPs for these groups are available from the existing
whole genome data).
Luxembourg samples were dominated by spa t003 and
t008, as has been described previously [10]. This primary
subtype composition indicates possible seeding of theTable 2 Genotyping PCR results from Assay
Validation panel
PCR Results No. Isolates % Isolates
spa t003* 2 1.3%
Branch C 14 9.0%
Branch D 40 25.6%
Branch F 1 0.6%
Branch G 37 23.7%
Branch H 11 7.1%
Branch I 5 3.2%
Branch J 7 4.5%
Branch K 0 0.0%
Branch L 5 3.2%
Branch N 4 2.6%
Branch O 2 1.3%
Branch P 3 1.9%
spa t008 18 11.5%
No Match 4 2.6%
Total # samples screened 153
* no subtype assignment.Luxembourg MRSA population from both Germany,
which has a dominant spa t003, and France, which has a
dominant spa t008 [8]. Luxembourg is a small country,
in area (2,586 km2) and population (~520,000), and is
situated between France, Germany and Belgium, and has
daily commuter, business and visitor travel from these
countries. A recent estimate puts the commuter population
at approximately 150,000 individuals per day [19]. As such,
Luxembourg’s pathogen and commensal ecology is heavily
influenced by its neighboring countries. Due to this domi-
nance of t003 and t008, these assays provide distinct utility
within Luxembourg. Subtyping methodologies in any re-
gion will need to be tied to the local strain populations and
may require multiple approaches or a more comprehensive
pan-genome approach such whole genome analysis.
The whole genome sequence analysis here provided
not only an ability to accurately identify phylogenetically
informative SNPs but also the ability to conduct whole
genome SNP typing (WGST) to compare to the SNP
assays, spa typing, MLVA and MLST. WGST has been pre-
viously used for advanced molecular typing of MRSA
[20,21], as well as for other bacteria [22,23] and fungal
pathogens [24-26]. WGST has proven to be far superior to
other typing methodologies for determining genetic assign-
ment (genotype) and phylogenetic relatedness (phylotype),
given its ability to interrogate genome-wide character
states. The WGST and SNP assays closely matched for the
Long Term Care Facility isolates, with WGST providing
far greater resolution. The identification of multiple clus-
ters of genomically related (i.e., separation by strains by 2
to 10 SNPs) within respective facilities may represent on-
going localized outbreaks within those facilities. These rela-
tionships were not apparent by other genotyping analyses.
The phylogeny of all spa t003 isolates in the present
study, as established by WGST, shows distinct sub-clades,
each containing multiple strains, as well as distinct lineages
containing solitary strain representatives. This provides evi-
dence of a well-established and diverse clonal structure in
Luxembourg. The diversity is possibly fostered through
both local evolution of spa t003 isolates within Luxembourg
as well as continual feeding of spa t003 isolates from
other t003 dominant countries, such as Germany. WGST-
based phylotyping of MRSA t003 strains from predominant
commuter-source communities in Germany would be
needed to test this hypothesis. Although not studied here,
there may be a similar phenomenon with t008 isolates, also
possibly having both local evolution and a continual influx
of diverse strains from t008 dominant countries (e.g.,
France and Belgium) [8,27].
Figure 4 Whole genome SNP typing (WGST) phylogeny of Long Term Care Facility strains with assay results. The phylogenetic
relationships are based on a total of 1434 SNPs out of which 686 were parsimony informative. The CI is 0.99. Numbers next to branches are
numbers of SNPs. The first number in genome name is the facility ID number and the second number is the isolate ID number. Facility linked
clusters are highlighted with brackets. Results of the SNP assays in the inset table indicate strain genotypes.
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Accurate and resolute genotyping of MRSA (and other
bacterial) strains representing dominant clones is neces-
sary to establish true relationships among strains for
molecular epidemiological purposes. With the advent of
new whole genome exploration tools, we are better able
to understand phylogenetic linkage between and among
strains. This movement from establishing genotype to es-
tablishing phylotype will prove powerful for public health
and clinical medicine. SNP-based genotyping assays using
real-time PCR are rapid and robust tools for establishing
phylotype, as we have shown here. As real-time PCR is a
widely accepted methodology in public health and com-
plex clinical laboratories, including at the LNS laboratory
in Luxembourg, these assays will advance the capability to
resolve spa t003 strains. In particular, exclusionary inter-
pretation is possible where an isolate can be shown not to
be a member of a particular clade. A lack of membership
strongly excludes a recent common evolutionary source,
whereas co-membership within a clade is only sugges-
tive. The use of real-time assays provides a significant im-
provement in time to answer, with results obtained within
2-6 hours (depending on individual laboratory’s sample
throughput, preferred extraction methodologies and in-
strumentation). Per sample costs also vary depending on
pooling capabilities and sample throughput, however,
costs will generally be less than $25 (USD) per sample. As
real-time PCR has become widely implemented, these as-
says should be readily adaptable by technical staff in any
laboratory using this technology.
In the coming years, whole genome sequencing will
likely play a primary role in genotyping. Next generation
sequencing not only allowed for identification of infor-
mative branch-specific markers for rapid genotyping, but
also provided further evidence that WGST is the most
robust and informative tool for phylotyping strains in
outbreak and non-outbreak related scenarios. Currently,
this analysis can be done on “tabletop” sequencers (i.e.,
Illumina MiSeq) within 36 hours for as little as $50 (USD)
per sample in sequence reagent costs. As these newer se-
quencing technologies become even more affordable and
portable, and the computational tools become more ac-
cessible, it is likely that we will continue to see greater
movement towards whole genome analysis for molecular
epidemiology and diagnostics of MRSA and other critical
pathogens.Additional files
Additional file 1: Table S1. Isolate and typing data for Assay
Development Panel strains.
Additional file 2: Table S2. Isolate and metadata for Assay Validation
Panel strains.Additional file 3: Table S3. Isolate and metadata for long term care
facility strain panel.
Additional file 4: Table S4. SNP Assay Results for Prospective Hospital
Panel.
Additional file 5: Table S5. Publically available genomes included in
phylogeny for Figure 1.
Additional file 6: Table S6. Primer and probe sequences for each Real
Time PCR Assay.
Additional file 7: Figure S1. Phylogenetic (A) and topology (B) trees of
initial forty strains. The phylogenetic relationships are based on a total of
13,614 SNPs with a CI = 0.97. Numbers next to branches are bootstrap
values of 100 replicates. Branch location of SNP assay targets for
identifying spa t003 and t008 are indicated with a red triangle.
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